IntelGenx Technologies Corp. announced that Montelukast VersaFilm® has been administered to the first Parkinson?s Disease (?PD?) patients in the Phase 2 (?MONTPARK?) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD.

The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx?s previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study?s Lead Principal Investigator.